Two years have passed since we first gathered together researchers from around the world to exchange their thoughts and data. Since that meeting in Hamburg, Germany, the evidence has grown that ADMA plays a significant role in cardiovascular physiology and pathology. The rapid growth of the field compelled a second meeting, held in New Orleans in November 2004. This issue of Vascular Medicine contains the proceedings from that meeting, at which new and exciting data emerged, of scientific interest and clinical relevance.
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ADMA is asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide (NO) synthase. ADMA has been recognized as a metabolite since the 1970s, but its functional role as a competitive inhibitor of NO synthase was first described by one of us (PV) in 1992. 1 Although the importance of this molecule was immediately apparent to endothelial biologists, ADMA did not attract the attention of the general scientific and clinical community until recently. Cardiologists, nephrologists, pharmacologists and others are currently among those who are actively pursuing research on ADMA. This is witnessed by the rapidly increasing number of scientific publications on the topic (the numeric results of a recent MEDLINE search are displayed in Figure 1 ). We anticipate a surge in interest from clinical investigators now that the scientific foundation has been laid, and now there are high throughput technologies for measurement of ADMA.
In October 2002, first attempts were made to understand the biosynthesis and metabolism of ADMA as well as some of its biological effects in the cardiovascular system. During our discussions at the first meeting in 2002 it became clear that an effort was needed to standardize analytical methods to measure ADMA because data generated by different groups of researchers and by different methods varied widely. At that time, the first studies had been published, which showed a relationship between ADMA and cardiovascular endpoints in controlled clinical trials. [2] [3] [4] By November 2004, the role of ADMA as an emerging cardiovascular risk factor had been much more firmly established by multiple studies in different patient populations. The physiological importance of ADMA has been strongly supported by observations made using the DDAH transgenic mouse. 5 Early results from a DDAH knockout mouse appear to be consistent with the role of ADMA as a negative regulator of NO synthase. The mechanisms by which ADMA becomes elevated in patients with cardiovascular disease have been elucidated (for recent reviews see Böger 2003, 6 Cooke 2004, 7 Vallance and Leiper 2004 8 ). Several therapeutic agents have been shown to reduce plasma ADMA levels in patients and those with risk factors, including angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, and insulin sensitizing agents (metformin and rosiglitazone). However, we are still lacking specific interventions to reduce plasma ADMA.
All of these new data, as they were presented during the Second International Symposium on ADMA -an Emerging Cardiovascular Risk Factor, are condensed into this supplemental issue to Vascular Medicine. This supplement provides a comprehensive overview on ADMA for researchers and clinicians alike who are interested in this emerging field of vascular biology and medicine.
Certainly, there are still open questions: What are the exact levels of ADMA in various tissues? Which isoform of DDAH contributes to its metabolism in various diseases? Is ADMA a widely applicable disease marker useful for primary prevention in patients with severe disease? Large prospective clinical trials will be needed to answer these questions; however, we feel that the stage is set to do so, and we anticipate that we will have more answers to these questions when we reconvene in London in 2006.
